Finance

Lists
Why is DHR up 3,34%?
Dive Deeper
DHR:NYSE
Danaher Corp
USD 221,21
+3,34%
(+7,14) 1D
USD 222,95
+0,79% (+1,74)
Pre-market
Closed: 5 Okt., 16:01:49 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DHR...
Open
USD 213,81
High
USD 222,15
Low
USD 213,44
Mkt. cap
155,51 mjd
Avg. vol.
3,93 m
Volume
3,10 k
Dividend
0,72%
Quarterly dividend
USD 0,40
Ex-dividend date
30 Sep. 2026
P/E ratio
39,27
52-wk high
USD 242,80
52-wk low
USD 160,93
EPS
USD 5,63
Beta
0,77
Shares outstanding
702,99 m
No. of employees
59 k
Open
USD 213,81
High
USD 222,15
Low
USD 213,44
Mkt. cap
155,51 mjd
Avg. vol.
3,93 m
Volume
3,10 k
Dividend
0,72%
Quarterly dividend
USD 0,40
Ex-dividend date
30 Sep. 2026
P/E ratio
39,27
52-wk high
USD 242,80
52-wk low
USD 160,93
EPS
USD 5,63
Beta
0,77
Shares outstanding
702,99 m
No. of employees
59 k
News stories
From web sources and news partners
Profile
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing. The company is ranked 180th on the Fortune 500 and 241st on the Forbes Global 2000. Wikipedia
About Danaher Corp
CEORainer M. Blair
Employees59 k
Founded1969
Headquarters-
SectorHealth care
Analyst ratings
Based on 17 analysts giving stock ratings to DHR in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for DHR in the last 3 months.
Highest
Current USD 221,21
USD 250,00 (+13,01%)
Average
USD 229,75 (+3,86%)
Lowest
USD 200,00 (-9,59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Evie Koslosky
Goldman Sachs
Buy
Maintained
USD 250,00
+13%
10/05/2026
Dan Leonard
RBC Capital
Buy
Maintained
USD 250,00
+13%
10/04/2026
Subbu Nambi
Guggenheim
Buy
Maintained
USD 250,00
+13%
10/01/2026
Joanne Wuensch
Citi
Buy
Maintained
USD 230,00
+4%
09/21/2026
Tycho Peterson
Jefferies
Buy
Maintained
USD 210,00
-5,1%
09/18/2026
Doug Schenkel
UBS
Buy
Initiated
USD 250,00
+13%
09/13/2026
Lu Li
UBS
Buy
Initiated
USD 250,00
+13%
09/09/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Maintained
USD 220,00
-0,5%
08/03/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
USD 230,00
+4%
08/03/2026
Luke Sergott
Barclays
Buy
Maintained
USD 230,00
+4%
08/04/2026
David Westenberg
Piper Sandler
Hold
Maintained
USD 200,00
-9,6%
07/27/2026
David Toung
Argus Research
Buy
Reiterated
USD 230,00
+4%
07/23/2026
Casey Woodring
J.P. Morgan
Buy
Maintained
USD 220,00
-0,5%
07/23/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
USD 240,00
+8,5%
07/22/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/22/2026
Daniel Arias
Stifel Nicolaus
Buy
Maintained
USD 220,00
-0,5%
07/22/2026
Patrick B Donnelly
Citi
Buy
Maintained
USD 230,00
+4%
07/22/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
USD 195,00
-11,8%
07/22/2026
Daniel Brennan
TD Cowen
Buy
Reiterated
USD 236,00
+6,7%
07/22/2026
Aristotelis Moutopoulos
DZ BANK AG
Buy
Maintained
USD 210,00
-5,1%
07/22/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
USD 230,00
+4%
07/06/2026
Unknown Analyst
DZ BANK AG
Buy
Initiated
USD 210,00
-5,1%
06/03/2026
Sidharth Sahoo
HSBC
Buy
Maintained
USD 230,00
+4%
06/03/2026
Michael Polark
Wolfe Research
Hold
Downgraded
-
-
06/01/2026
Unknown Analyst
RBC Capital
Buy
Initiated
USD 200,00
-9,6%
05/14/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
USD 245,00
+10,8%
04/22/2026
Ed Ridley-Day
Rothschild & Co Redburn
Hold
Maintained
USD 205,00
-7,3%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
USD 230,00
+4%
04/14/2026
Last report
21 Jul. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
USD 1,94 / USD 1,84
+5,28%beat
Revenue / Est. (USD)
6,26 mjd / 6,17 mjd
+1,53%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
6,05 mjd
6,84 mjd
5,95 mjd
6,26 mjd
Cost of goods sold
2,53 mjd
2,86 mjd
2,36 mjd
2,61 mjd
Cost of revenue
2,53 mjd
2,86 mjd
2,36 mjd
2,61 mjd
Research and development expenses
378,00 m
438,00 m
387,00 m
412,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,89 mjd
2,03 mjd
1,84 mjd
2,01 mjd
Operating expense
2,27 mjd
2,46 mjd
2,23 mjd
2,42 mjd
Total operating expenses
4,80 mjd
5,32 mjd
4,59 mjd
5,03 mjd
Operating income
1,26 mjd
1,52 mjd
1,36 mjd
1,24 mjd
Other non operating income
-
-87,00 m
-
-
EBT including unusual items
1,08 mjd
1,37 mjd
1,24 mjd
1,08 mjd
EBT excluding unusual items
1,19 mjd
1,39 mjd
1,33 mjd
1,19 mjd
Income tax expense
168,00 m
190,00 m
206,00 m
208,00 m
Effective tax rate
15,61%
13,84%
16,68%
19,29%
Other operating expenses
-
-
-
-
Net income
908,00 m
1,20 mjd
1,03 mjd
870,00 m
Net profit margin
-
-
-
-
Earnings per share
1,89
2,23
2,06
1,94
Interest and investment income
3,00 m
13,00 m
27,00 m
61,00 m
Interest expense
-67,00 m
-55,00 m
-63,00 m
-107,00 m
Net interest expenses
-64,00 m
-42,00 m
-36,00 m
-46,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,88 mjd
2,14 mjd
1,99 mjd
1,90 mjd
Gain or loss from assets sale
-9,00 m
9,00 m
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google-programme